MARKET

IMUX

IMUX

Immunic Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.41
+0.77
+4.92%
Pre Market: 17.67 +1.26 +7.68% 08:34 09/28 EDT
OPEN
15.35
PREV CLOSE
15.64
HIGH
16.57
LOW
15.31
VOLUME
432.13K
TURNOVER
--
52 WEEK HIGH
23.39
52 WEEK LOW
4.190
MARKET CAP
327.68M
P/E (TTM)
-5.0305
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Immunic mid-stage study of IMU-838 in COVID-19 patients passes first safety tollgate
Immunic (IMUX) announces that its Phase 2 clinical trial, CALVID-1, evaluating IMU-838 in patients with moderate COVID-19 disease will continue unchanged after the independent Data Monitoring Committee completed its preplanned
Seekingalpha · 59m ago
Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced the results of a pre-planned interim safety analysis and a recruitment update from the
PR Newswire · 2h ago
Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the full unblinded clinical data set from the company's phase 2 EMPhASIS trial
PR Newswire · 09/11 10:30
Immunic, Inc. to Participate in Scientific and Investor Conferences in September
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in September:
PR Newswire · 09/08 10:30
CRM, GTX, PLAN and URBN among midday movers
Gainers: Fluidigm Corporation (FLDM) +33%.SCWorx (WORX) +29%.Anaplan (PLAN) +29%.salesforce.com (CRM) +27%.Cryoport (CYRX) +26%.Lipocine (LPCN) +23%.Immunic (IMUX) +22%.Fluent (FLNT) +22%.BigCommerce Holdings (BIGC) +22%.Urban Outfitters (URBN) +21%.Losers: Garrett Motion (GTX) -42%. Outlook Therapeutics (OTLK)
Seekingalpha · 08/26 16:34
Immunic and Lipocine among healthcare gainers; Outlook Therapeutics leads the losers
Gainers: SCWorx (WORX) +37%. Immunic (IMUX) +23%. Fluidigm (FLDM) +22%. CNS Pharmaceuticals (CNSP) +20%. Lipocine (LPCN) +17%.Losers: Outlook Therapeutics (OTLK) -32%. CohBar (CWBR) -31%. Keros Therapeutics (KROS) -11%. Orchard Therapeutics (ORTX) -11%. Ovid Therapeutics (OVID)
Seekingalpha · 08/26 15:04
Benzinga's Top Upgrades, Downgrades For August 26, 2020
Upgrades * Evercore ISI Group upgraded the previous rating for The Hain Celestial Group Inc (NASDAQ: HAIN) from In-Line to Outperform. In the fourth quarter, Hain Celestial Group showed an EPS of $0.32, compared to $0.21 from the year-ago quarter. The stock has a 52-week-high of $34.53 and a 52-week-low
Benzinga · 08/26 13:42
CRM, HPE among premarket gainers
Tyme Technologies (TYME) +29% as oncology research reveals potential new oral therapy TYME-19 in the fight against COVID-19.SCWorx (WORX) +32%.Immunic (IMUX) +20% as Piper goes bargain shopping.Heat Biologics (HTBX) +19%
Seekingalpha · 08/26 12:21
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMUX. Analyze the recent business situations of Immunic Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMUX stock price target is 62.67 with a high estimate of 71.00 and a low estimate of 56.00.
EPS
Institutional Holdings
Institutions: 61
Institutional Holdings: 4.39M
% Owned: 21.99%
Shares Outstanding: 19.97M
TypeInstitutionsShares
Increased
12
603.91K
New
32
1.52M
Decreased
4
33.22K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.04%
Pharmaceuticals & Medical Research
+1.58%
Key Executives
President/Chief Executive Officer/Director
Daniel Vitt
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
Glenn Whaley
Chief Operating Officer
Manfred Groppel
Chief Scientific Officer
Hella Kohlhof
Other
Andreas Muehler
Independent Director
Tamar Howson
Independent Director
Jorg Neermann
Independent Director
Vincent Ossipow
Independent Director
Barclay Phillips
Independent Director
Jan Van den Bossche
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IMUX
Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Immunic Inc stock information, including NASDAQ:IMUX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMUX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMUX stock methods without spending real money on the virtual paper trading platform.